Previous 10 | Next 10 |
home / stock / gnftf / gnftf news
2023-05-11 16:04:46 ET Summary Results from the phase 3 ELATIVE study, using elafibranor to treat patients with primary biliary cholangitis, are expected to be released before end of Q2 of 2023. The primary biliary cholangitis market is expected to reach $1.7 billion by 2029. ...
Lille ( France ) ; Cambridge ( Massachusetts, United States) ; Zurich (Switzerland); May 9 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and sev...
GENFIT Announces Publication of Extra-Financial Performance Report 2022 Lille ( France ) ; Cambridge, ( Massachusetts, United States ) ; Zurich (Switzerland); April 2 7 , 202 3 - GENFIT (Nasdaq and Euronext: G...
Lille ( France ) ; Cambridge ( Massachusetts, United States ) ; Zurich (Switzerland) ; April 19 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with sev...
Lille ( France ) ; Cambridge ( Massachusetts, United States) ; Zurich (Switzerland); April 18 , 202 3 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe ch...
Cash, cash equivalents and current financial assets totaled €140.2 million 1 as of December 31, 2022, expected to fund operations through third quarter 2024 Transformative milestone expected towards end of second quarter 2023, with topline data readout for Phase 3 ELATI...
Cash, cash equivalents and current financial instruments totaled €140.2 million as of December 31, 2022. Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); February 28, 2023 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutic...
Summary Albireo, Mirum Pharmaceuticals, Inc.'s only competitor in a billion-dollar market, is being acquired by Ipsen for up to $1.2 billion. The biggest value driver of Mirum is Livmarli, currently the only approved life-saving product in a rare pediatric disease market worth $500 mill...
Lille (France ), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 24 , 202 3 – GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized ...
Lille (France ), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 5 , 202 3 – GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized b...
News, Short Squeeze, Breakout and More Instantly...
Genfit Ord Company Name:
GNFTF Stock Symbol:
OTCMKTS Market:
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the inclusi...
Ipsen’s Iqirvo ® (elafibranor) 80 mg tablets receives U.S. FDA accelerated approval as a first-in-class treatment for Primary Biliary Cholangitis (PBC) First-ever drug developed in-house by GENFIT to achieve U.S. FDA’s approval GENFIT is eligible to ...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 29, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today detailed its presence ...